Skip to main content

Advertisement

SpringerLink
Log in

Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

In patients with rheumatoid arthritis (RA), weight is an important prognostic factor. Preliminary evidence has indicated that treatment with anti-tumour necrosis factor (TNF) therapy can affect the weight of patients with RA, but the relationship between improved prognosis and weight changes remains to be clarified. Our aim was to investigate the effects of anti-TNF therapy on the weight of patients with RA following 24 months of treatment. Patients (n = 168) were selected for this retrospective analysis on the basis of having received anti-TNF therapy for the first time. Change in body weight after 12 and 24 months of treatment was calculated and analysed by multiple regression analysis using age, sex, baseline body mass index (BMI), baseline DAS28 score, disease-modifying antirheumatic drug use, steroid use and specific anti-TNF drug as explanatory variables. The mean weight change of the patient group after 12 months of treatment was +1.58 kg (95% CI 0.71 to 2.46 kg) and after 24 months was +1.80 kg (95% CI 0.69 to 2.67 kg). After 24 months, 64.3% of patients had gained weight. There was no statistically significant association between weight gain at 12 or 24 months and age, sex, steroid use at baseline, anti-TNF drug or baseline DAS28 score. Baseline BMI had a statistically significant negative association with weight gain at 12 and 24 months. RA patients with lower BMIs tend to gain weight with anti-TNF therapy. Further studies are required to determine if the weight gained is fat and/or muscle and the effects upon general health outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Munro R, Capell H (1997) Prevalence of low body mass in rheumatoid arthritis: association with the acute phase response. Ann Rheum Dis 56(5):326–329

    Article  PubMed  CAS  Google Scholar 

  2. Helliwell M, Coombes EJ, Moody BJ, Batstone GF, Robertson JC (1984) Nutritional status in patients with rheumatoid arthritis. Ann Rheum Dis 43(3):386–390

    Article  PubMed  CAS  Google Scholar 

  3. Fleming A, Crown JM, Corbett M (1976) Prognostic value of early features in rheumatoid disease. Br Med J 1(6020):1243–1245

    Article  PubMed  CAS  Google Scholar 

  4. Kaufmann J, Kielstein V, Kilian S, Stein G, Hein G (2003) Relation between body mass index and radiological progression in patients with rheumatoid arthritis. J Rheumatol 30(11):2350–2355

    PubMed  Google Scholar 

  5. Kaufmann JVA, Muller A (2001) Synovial collagen II degradation correlates inversely with the body mass index in rheumatoid arthritis. Z Rheumatol 60(Suppl 1):I/77

    Google Scholar 

  6. Westhoff G, Rau R, Zink A (2007) Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthritis Rheum 56(11):3575–3582

    Article  PubMed  CAS  Google Scholar 

  7. Walsmith J, Roubenoff R (2002) Cachexia in rheumatoid arthritis. Int J Cardiol 85(1):89–99

    Article  PubMed  Google Scholar 

  8. Giles JT, Ling SM, Ferrucci L, Bartlett SJ, Andersen RE, Towns M et al (2008) Abnormal body composition phenotypes in older rheumatoid arthritis patients: association with disease characteristics and pharmacotherapies. Arthritis Rheum 59(6):807–815

    Article  PubMed  Google Scholar 

  9. Summers GD, Deighton CM, Rennie MJ, Booth AH (2008) Rheumatoid cachexia: a clinical perspective. Rheumatology (Oxford) 47(8):1124–1131

    Article  CAS  Google Scholar 

  10. Summers GD, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD (2010) Rheumatoid cachexia and cardiovascular disease. Nat Rev Rheumatol 6(8):445–451

    Article  PubMed  Google Scholar 

  11. Taylor PC, Feldmann M (2009) Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 5(10):578–582

    Article  PubMed  CAS  Google Scholar 

  12. Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ (2006) Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 84(6):1463–1472

    PubMed  CAS  Google Scholar 

  13. National Institute for Health and Clinical Excellence (2009) Rheumatoid arthritis: the management of rheumatoid arthritis in adults. Clinical Guidelines CG79. National Institute for Health and Clinical Excellence, London

    Google Scholar 

  14. Metsios GS, Stavropoulos-Kalinoglou A, Douglas KM, Koutedakis Y, Nevill AM, Panoulas VF et al (2007) Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia. Rheumatology (Oxford) 46(12):1824–1827

    Article  CAS  Google Scholar 

  15. Alcorn N, Tierney A, Wu O, Gilmour H, Madhok R (2010) Impact of anti-tumour necrosis factor therapy on the weight of patients with rheumatoid arthritis. Ann Rheum Dis 69(8):1571

    Article  PubMed  Google Scholar 

  16. Engvall IL, Tengstrand B, Brismar K, Hafstrom I (2010) Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. Arthritis Res Ther 12(5):R197

    Article  PubMed  Google Scholar 

  17. Briot K, Gossec L, Kolta S, Dougados M, Roux C (2008) Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment. J Rheumatol 35(5):855–861

    PubMed  CAS  Google Scholar 

  18. Briot K, Garnero P, Le Henanff A, Dougados M, Roux C (2005) Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor alpha treatment. Ann Rheum Dis 64(8):1137–1140

    Article  PubMed  CAS  Google Scholar 

  19. Saraceno R, Schipani C, Mazzotta A, Esposito M, Di Renzo L, De Lorenzo A et al (2008) Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 57(4):290–295

    Article  PubMed  CAS  Google Scholar 

  20. Prignano F, Ricceri F, Pescitelli L, Buggiani G, Troiano M, Zanieri F et al (2009) Comparison of body weight and clinical-parameter changes following the treatment of plaque psoriasis with biological therapies. Curr Med Res Opin 25(9):2311–2316

    Article  PubMed  CAS  Google Scholar 

  21. Esposito M, Mazzotta A, Saraceno R, Schipani C, Chimenti S (2009) Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis. Int J Immunopathol Pharmacol 22(1):219–225

    PubMed  CAS  Google Scholar 

  22. Gisondi P, Cotena C, Tessari G, Girolomoni G (2008) Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 22(3):341–344

    Article  PubMed  CAS  Google Scholar 

  23. Alcorn N, Saunders S, Madhok R (2009) Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 32(12):1123–1134

    Article  PubMed  CAS  Google Scholar 

  24. Naranjo A, Sokka T, Descalzo MA, Calvo-Alen J, Horslev-Petersen K, Luukkainen RK et al (2008) Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 10(2):R30

    Article  PubMed  Google Scholar 

  25. Rall LC, Roubenoff R (2004) Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology (Oxford) 43(10):1219–1223

    Article  CAS  Google Scholar 

  26. Seror R, Dougados M, Gossec L (2009) Glucocorticoid sparing effect of tumour necrosis factor alpha inhibitors in rheumatoid arthritis in real life practice. Clin Exp Rheumatol 27(5):807–813

    PubMed  CAS  Google Scholar 

Download references

Disclosures

None.

Author information

Authors and Affiliations

  1. Department of Rheumatology, Royal Derby Hospital, Uttoxeter Road, Derby, DE22 3NE, UK

    Rachel A. Brown, Sayqa Butt & Gregory D. Summers

  2. Sackler Institute of Pulmonary Pharmacology, Pharmaceutical Sciences Division, King’s College London, London, UK

    Domenico Spina

Authors
  1. Rachel A. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Domenico Spina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sayqa Butt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gregory D. Summers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gregory D. Summers.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brown, R.A., Spina, D., Butt, S. et al. Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis. Clin Rheumatol 31, 455–461 (2012). https://doi.org/10.1007/s10067-011-1863-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-011-1863-6

Keywords

Search

Navigation